ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Session » Poster Session 3

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

Date: Saturday, May 2, 2020

Time: 4:15PM-5:15PM

Meeting: 2020 Pediatric Rheumatology Symposium

4:15PM-5:15PM
Abstract Number: 165
A Massively Parallel Reporter Assay Screen of Genetic Variants on JIA Haplotypes Reveals Variants Associated with Altered Function of an Intergenic Enhancer in the HLA Class II Locus
4:15PM-5:15PM
Abstract Number: 188
A New Multidisciplinary Pediatric SLE Clinic in a Large Urban Care Center: Feasibility, Patient Satisfaction, and Quality After One Year
4:15PM-5:15PM
Abstract Number: 184
A Survey of Uveitis Knowledge Among Juvenile Arthritis Patients and Parents
4:15PM-5:15PM
Abstract Number: 119
Actual Medication Usage of Patients with Juvenile Onset Systemic Lupus Erythematosus Using Japanese Health Insurance Database
4:15PM-5:15PM
Abstract Number: 186
Anthropometric Assessment and Food Intake of Parents of Pediatric Patients with Chronic Rheumatic Diseases
4:15PM-5:15PM
Abstract Number: 145
Anti-Citrullinated Protein Antibodies (ACPA) and Bony Erosions in Polyarticular JIA
4:15PM-5:15PM
Abstract Number: 163
Anti-Dense Fine Speckled (DFS) Autoantibodies in Autoinflammatory Vasculopathies
4:15PM-5:15PM
Abstract Number: 130
Anti-Ro/SSA Is Associated with Progression to End-Stage Renal Disease in Anti-dsDNA Positive Lupus Nephritis
4:15PM-5:15PM
Abstract Number: 115
Carbohydrate and Sugar Intake Predict Pain in Teens with Active JIA Disease but Not in Teens in Remission or Controls: A Cross-Sectional, Case-Control Metabolomics Pilot Study
4:15PM-5:15PM
Abstract Number: 160
CD3 Downregulation on T-cells Is Concomitant with Arginase Upregulation on Myeloid Cells in Synovial Fluid of Patients with Juvenile Idiopathic Arthritis
4:15PM-5:15PM
Abstract Number: 120
Characteristics of the New Childhood Arthritis and Rheumatology Research Alliance Registry of Juvenile Myositis Patients Enrolled in the First Two Years
4:15PM-5:15PM
Abstract Number: 148
Chronic Fatigue Symptoms in Children with Abrupt Early-onset OCD And/or PANS
4:15PM-5:15PM
Abstract Number: 132
Clinical Characteristics and Outcomes of Critically Ill Children Requiring Rheumatology Consultation in a Large Intensive Care Unit
4:15PM-5:15PM
Abstract Number: 183
Collaboration Between Rheumatology Clinic and Specialty Pharmacy to Positively Impact Patient Experience and Hospital Stewardship
4:15PM-5:15PM
Abstract Number: 126
Cyclophosphamide as Rescue Therapy for Kawasaki Disease with Peripheral Vascular Disease: A Single Center Experience
4:15PM-5:15PM
Abstract Number: 141
Cyclophosphamide Use in Treatment of Refractory Kawasaki Disease: A Single Center Case Series of 10 Patients and Literature Review
4:15PM-5:15PM
Abstract Number: 127
Disease Characteristics and Medication Utilization in Lupus Nephritis Associated with Childhood-Onset Systemic Lupus Erythematosus
4:15PM-5:15PM
Abstract Number: 121
Evaluating the Relationship Between Juvenile Idiopathic Arthritis Disease Activity and Uveitis Activity: A Retrospective Analysis
4:15PM-5:15PM
Abstract Number: 113
Evaluation of B-cell Depletion with Rituximab and IVIG Concurrent Treatment in Pediatric Autoimmune Brain Disease
4:15PM-5:15PM
Abstract Number: 134
Evaluation of Self-report Screening Measures in the Detection of Depressive and Anxiety Disorders Among Children and Adolescents with Systemic Lupus Erythematosus
4:15PM-5:15PM
Abstract Number: 193
Examining Social Loafing and the Free-Rider Effect in Transition Readiness Among Youth with jSLE
4:15PM-5:15PM
Abstract Number: 168
Examining the Role of IFN-I and Langerhans Cell ADAM17 in Lupus Photosensitivity
4:15PM-5:15PM
Abstract Number: 144
Failure of Methotrexate Monotherapy and Subsequent Response to Tumor Necrosis Factor Inhibitors in Pediatric Non-Infectious Uveitis
4:15PM-5:15PM
Abstract Number: 147
Familial Clustering of Immune-mediated Diseases in Children with Abrupt-onset OCD
4:15PM-5:15PM
Abstract Number: 117
Family Impact of Juvenile Localized Scleroderma
4:15PM-5:15PM
Abstract Number: 125
Feasibility and Pilot Study of Mental Health Screening in Juvenile Myositis
4:15PM-5:15PM
Abstract Number: 181
Health Care Professionals and Transition to Adulthood for Youth with Juvenile Idiopathic Arthritis
4:15PM-5:15PM
Abstract Number: 146
Immersive Virtual Reality for Management of Amplified Musculoskeletal Pain Syndrome in Adolescents: A Pilot Randomized Controlled Trial
4:15PM-5:15PM
Abstract Number: 143
Immunological Profiles Following Treatment with Rituximab in Autoimmune Disease
4:15PM-5:15PM
Abstract Number: 161
Impact of the Month of Birth on the Development of Juvenile Idiopathic Arthritis in the United States
4:15PM-5:15PM
Abstract Number: 189
Influenza Immunization: A Quality Assurance Survey in a Pediatric Rheumatology Clinic
4:15PM-5:15PM
Abstract Number: 180
Influenza Knowledge and Barriers to Vaccination in Immunosuppressed Patients in the Pediatric Rheumatology Clinic
4:15PM-5:15PM
Abstract Number: 159
Interleukin-18 as a Key Cytokine to Understand Pathology and to Decide Appropriate Therapeutic Strategy in Chronic Arthritic Systemic Juvenile Idiopathic Arthritis
4:15PM-5:15PM
Abstract Number: 123
Juvenile Spondyloarthritis in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry: High Biologic Use, Low Prevalence of HLA-B27, and Equal Sex Representation in Those with Sacroiliitis
4:15PM-5:15PM
Abstract Number: 167
Lipidomic Profiles of Synovial Fluid from Patients with Oligoarticular Juvenile Idiopathic Arthritis Naïve to Treatment
4:15PM-5:15PM
Abstract Number: 118
Long-Term Outcomes in Children Born to Anti-Ro and/or anti-La Positive Mothers
4:15PM-5:15PM
Abstract Number: 137
Measuring Decision Conflict in Parents of Children with Juvenile Idiopathic Arthritis When Making the Decision to Begin Disease Modifying Anti-Rheumatic Drugs or Biologic Agents
4:15PM-5:15PM
Abstract Number: 162
Minor Biomarkers in Juvenile Idiopathic Arthritis (JIA)
4:15PM-5:15PM
Abstract Number: 114
Musculoskeletal Ultrasound Study in Childhood Arthritis: A Limited Examination
4:15PM-5:15PM
Abstract Number: 182
Needs of Youth with Juvenile Idiopathic Arthritis During the Transition to Adulthood
4:15PM-5:15PM
Abstract Number: 179
New Juvenile Idiopathic Arthritis Quality Measure Set for the Pediatric Rheumatology Care and Outcomes Improvement Network
4:15PM-5:15PM
Abstract Number: 139
Ongoing Disease Activity in Juvenile Idiopathic Arthritis (JIA) 18 Years After Disease Onset: A Population-based Nordic Study
4:15PM-5:15PM
Abstract Number: 190
Outcomes of an Evidence Based Guideline for the Treatment of Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome
4:15PM-5:15PM
Abstract Number: 116
Patterns of Etanercept Use in the Childhood Arthritis and Rheumatology Research Alliance Juvenile Idiopathic Arthritis Registry
4:15PM-5:15PM
Abstract Number: 133
Pediatric Rheumatology Consultation for Both Traditional and Emerging Rheumatic Diseases in the Critical Care Setting
4:15PM-5:15PM
Abstract Number: 187
Perspectives of Adolescents and Young Adults Around Implementing Rheumatology Healthcare Transition: Preliminary Qualitative Findings
4:15PM-5:15PM
Abstract Number: 185
pGALS Training Increases Canadian and Kenyan Physicians’ Confidence in Examining the Musculoskeletal System in Children
4:15PM-5:15PM
Abstract Number: 124
Pharmacist Role in an Outpatient Adolescent Complex Pediatric Lupus Clinic
4:15PM-5:15PM
Abstract Number: 131
Practice Patterns for Consulting Pediatric Rheumatology in a Large Pediatric Intensive Care Unit
4:15PM-5:15PM
Abstract Number: 128
Predictors of Moderate/High Disease Activity in Childhood-Onset Systemic Lupus Erythematosus
4:15PM-5:15PM
Abstract Number: 136
Prevalence of Paradoxical Psoriasis After Exposure to Tumor Necrosis Factor Inhibitors (TNFi) in Children from a Single Tertiary Center
4:15PM-5:15PM
Abstract Number: 129
Reproductive Health Concerns in Young Adults with Pediatric Onset Rheumatic Diseases
4:15PM-5:15PM
Abstract Number: 166
Resident Memory T Cells in Human RA Synovium Display Restricted TCR Clones
4:15PM-5:15PM
Abstract Number: 138
Serious Infection Risk in Pediatric Patients with Low Immunoglobulin Levels Following Rituximab Treatment for Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)
4:15PM-5:15PM
Abstract Number: 140
Serum Biomarkers in a German Cohort of Patients with Systemic Juvenile Idiopathic Arthritis and Their Relationship to Response to Interleukin-1 Blockade
4:15PM-5:15PM
Abstract Number: 192
Single Center Consensus of Prophylactic Treatment in Immunocompromised Children with Rheumatic Disease
4:15PM-5:15PM
Abstract Number: 122
Systemic Inflammation and Cognitive Dysfunction in jSLE Patients
4:15PM-5:15PM
Abstract Number: 164
The Juvenile Idiopathic Arthritis-Associated IL2RA and IL6R Haplotypes Contain Enhancers Whose Functions Are Altered by JIA-Associated Genetic Variants
4:15PM-5:15PM
Abstract Number: 135
Use of Intravenous Pamidronate in Pediatric Leukemia Patients with Osteonecrosis Results in Reduced Pain and May Halt Osteonecrosis Progression
4:15PM-5:15PM
Abstract Number: 191
Utilization of Telemedicine in Pediatric Rheumatologic Care
4:15PM-5:15PM
Abstract Number: 142
WITHDRAWN

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology